½ÃÀ庸°í¼­
»óǰÄÚµå
1776189

¼¼°èÀÇ Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå : ½ÃÀå ÀλçÀÌÆ®, °æÀï ±¸µµ, ½ÃÀå ¿¹Ãø(2032³â)

Chest Drainage Catheters - Market Insights, Competitive Landscape, and Market Forecast - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DelveInsight | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È 4.78%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Èä°­ ¹è¾× Ä«Å×ÅÍ¿¡ ´ëÇÑ ¼ö¿ä´Â ¾Ï, ½ÉÇ÷°üÁúȯ, ¾Ç¼º Èä¼ö, ±âÈä, Ç÷Èä, ½É³¶¾× Àú·ù µî Èä°­ ¹è¾× ÁßÀç°¡ ÀÚÁÖ ÇÊ¿äÇÑ ¸¸¼ºÁúȯÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡¿Í °°Àº ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Ä«Å×ÅÍ ±â¼úÀÇ ¹ßÀü, ÀÇ·á ¼­ºñ½º Á¢±Ù¼º Çâ»ó, ÁÖ¿ä ½ÃÀå ÁøÀÔÀÚµéÀÇ Áö¼ÓÀûÀÎ Á¦Ç° Çõ½Å°ú ÇÔ²² ÀÌ·¯ÇÑ Áúº´À¸·Î ÀÎÇÑ ºÎ´ã Áõ°¡´Â ½ÃÀå È®´ë¸¦ ÃËÁøÇϴ ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇյǾî 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È Èä°­ ¹è¾× Ä«Å×ÅÍ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Çö´ë ÀÇÇп¡¼­ Èä°­ ¹è¾× Ä«Å×ÅÍÀÇ Áß¿äÇÑ ¿ªÇÒÀÌ °­È­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå ¿ªÇÐ:

±¹Á¦¾Ï¿¬±¸¼ÒÀÇ µ¥ÀÌÅÍ(2024³â)¿¡ µû¸£¸é, 2022³â º¸°íµÈ ±â°üÁö, ±â°üÁö, Æó¾Ï ȯÀÚ ¼ö´Â 248¸¸ 675°ÇÀ̾ú½À´Ï´Ù. ±× Áß ¾Æ½Ã¾Æ°¡ ÀüüÀÇ 63.1%¸¦ Â÷ÁöÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ ¾Ï, ƯÈ÷ Æó¾ÏÀº Á¾Á¾ Àç¹ß¼º Èä¼ö Àú·ù¸¦ µ¿¹ÝÇϸç, ¿ÏÈ­ Ä¡·á ¹× Ä¡·á Ä¡·á¸¦ À§ÇØ ÅͳÎÇü ¶Ç´Â ºñÅͳÎÇü Èä°­ ¹è¾× Ä«Å×Å͸¦ »ç¿ëÇÏ¿© °ü¸®µË´Ï´Ù. ¾ÏÀÇ ºÎ´ã, ƯÈ÷ ÁøÇà ´Ü°èÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º´¿ø, Á¾¾ç ¼¾ÅÍ ¹× ÀçÅÃÀÇ·á ÇöÀå¿¡¼­ ÀÌ·¯ÇÑ Ä«Å×ÅÍ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Á÷Á¢ÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¾¾çÇÐ ¿Ü¿¡µµ ½ÉÇ÷°üÁúȯÀÇ À¯Ç൵ Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿µ±¹ ½ÉÀåÀç´Ü(2024³â)¿¡ µû¸£¸é, Àü ¼¼°èÀûÀ¸·Î ¾à 6¾ï 2,000¸¸ ¸íÀÌ ½ÉÀå ¹× ¼øÈ¯±â ÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, Àü ¼¼°è 13¸í Áß 1¸íÀÌ ÀÌ·¯ÇÑ ÁúȯÀ» ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ½ÉÀ帶ºñ³ª ½ÉÀå ¼ö¼ú°ú °°Àº ½ÉÇ÷°üÁúȯÀº ½É³¶¾× Àú·ù³ª ¼ö¼ú ÈÄ Ã¼¾× Àú·ù¸¦ À¯¹ßÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, ½É³¶¿°À» ¿¹¹æÇϰí ȸº¹À» ÃËÁøÇϱâ À§ÇØ Æó¼âÇü Èä°­ ¹è¾× Ä«Å×Å͸¦ »ç¿ëÇØ¾ß ÇÕ´Ï´Ù.

¶ÇÇÑ, ÃÖ¼Òħ½ÀÀû ½Ã¼ú, µðÁöÅÐ ½Ã¼ú, ¿µ»ó À¯µµ ½Ã¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½Ã¼úÀÇ Á¤È®¼º, ȯÀÚ ¾ÈÀü ¹× ȸº¹ °á°ú¸¦ Çâ»ó½ÃÅ´À¸·Î½á Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½ÀÀû ½Ã¼úÀº ¿Ü»óÀ» ÁÙÀ̰í, °¨¿° À§ÇèÀ» ³·Ã߸ç, ÀÔ¿ø ±â°£À» ´ÜÃàÇϱ⠶§¹®¿¡ ÀÓ»óÀÇ¿Í È¯ÀÚ ¸ðµÎ ¼±È£Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ÃÊÀ½ÆÄ³ª Åõ½Ã°æÀ» ÀÌ¿ëÇÑ ¿µ»óÀ¯µµ Ä«Å×ÅÍ »ðÀÔÀº Á¤È®ÇÑ À§Ä¡ °áÁ¤ÀÌ °¡´ÉÇÏ¿© Á¶Á÷ ¼Õ»óÀ̳ª À§Ä¡ ÀÌ»ó µîÀÇ ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. À¯·® ¼¾¼­¿Í ¾Ð·Â ¸ð´ÏÅͰ¡ ÀåÂøµÈ ½º¸¶Æ® Ä«Å×ÅÍ¿Í °°Àº µðÁöÅÐ ±â¼úÀÇ ¹ßÀüÀ¸·Î ½Ç½Ã°£ ¹è¾× ¸ð´ÏÅ͸µ, ÇÕº´Áõ Á¶±â ¹ß°ß, ¼ö¼ú ÈÄ °ü¸® °³¼±ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ÀÓ»óÀû È¿À²¼º°ú ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó, ¿Ü·¡ Ä¡·á¿Í ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» ¼±È£ÇÏ´Â ¼¼°è ÇコÄÉ¾î Æ®·»µå¿Íµµ ºÎÇÕÇÕ´Ï´Ù.

µû¶ó¼­ Àü ¼¼°èÀûÀ¸·Î ¾Ï°ú ½ÉÀå ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾ÈÀüÇϰí È¿°úÀûÀ̸ç ÃÖ¼Òħ½ÀÀûÀÎ Èä°­ ¹è¾× ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª Èä°­ ¹è¾× Ä«Å×ÅÍ¿Í °ü·ÃµÈ º¹À⼺°ú Á¦ÇÑ, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç µîÀº Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ ¼ºÀåÀ» Á¦ÇÑÇÒ ¼ö ÀÖ´Â ÁÖ¿ä ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå ºÎ¹® ºÐ¼®:

Á¦Ç° À¯Çü(Èä°­ ¹è¾× Ä«Å×ÅÍ, È丷 ¹è¾× Ä«Å×ÅÍ, Æ®·ÎÄ¿ Ä«Å×ÅÍ, ±âŸ), ÀçÁú(½Ç¸®ÄÜ, PVC(Æú¸®¿°È­ºñ´Ò), ±âŸ), ¿ëµµ(ÈäºÎ¿Ü°ú, Èä¼ö, ¿Ü»ó¿Ü°ú, ±âÈä, ±âŸ), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ), Áö¿ª(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ±âŸ Áö¿ª)

Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ Á¦Ç° À¯Çüº°·Î´Â È丷 ¹è¾× Ä«Å×ÅÍ Ä«Å×°í¸®°¡ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. È丷 ¹è¾× Ä«Å×ÅÍ´Â Èä¼ö, ±âÈä, Ç÷Èä, Èä°­¿¡¼­ ü¾×À̳ª °ø±â¸¦ ¹èÃâÇØ¾ß ÇÏ´Â ±âŸ ÈäºÎ ÁúȯÀÇ °ü¸®¿¡¼­ »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àüü Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀ» Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù. Æó¾Ï, ¿ïÇ÷¼º ½ÉºÎÀü, °¨¿° ¹× ¿Ü»ó °ü·Ã È丷 ÁúȯÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È丷 ¹è¾× ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â ±Þ¼º±â ¹× Àå±â ¿ä¾ç ºÐ¾ß ¸ðµÎ¿¡¼­ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Ä«Å×ÅÍ, ƯÈ÷ PleurX(TM) ½Ã½ºÅÛ°ú °°Àº ÅͳÎÇü È丷 Ä«Å×ÅÍ(TIPC)´Â Àç¹ß¼º ¶Ç´Â ¸¸¼º Èä¼ö Àú·ù¸¦ °ü¸®ÇÏ´Â µ¥ ¼±È£µÇ´Â ¼Ö·ç¼ÇÀ¸·Î, ¹Ýº¹ÀûÀÎ Èä°­ õÀÚ³ª º´¿ø ½Ã¼ú¿¡ ´ëÇÑ ´ú ħ½ÀÀûÀÎ ¿Ü·¡ ±â¹Ý ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ Ä«Å×ÅÍ´Â ¹Ýº¹ÀûÀÎ ÈäºÎ õÀÚ³ª º´¿ø ½Ã¼ú¿¡ ´ëÇÑ ´ú ħ½ÀÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇϸç, ¿Ü·¡ ȯÀÚ³ª ÀçÅà ȯÀÚµµ Ä¡·áÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ÃÖ¼Òħ½ÀÀû ¿Ü·¡ Ä¡·á·ÎÀÇ ÀüȯÀº ºñ¿ë Àý°¨, ÀÔ¿ø ±â°£ ´ÜÃà, ȯÀÚ ÆíÀǼº Çâ»ó µî ±¤¹üÀ§ÇÑ ÇコÄÉ¾î Æ®·»µå¿Í ÀÏÄ¡Çϸç È丷 ¹è¾× Ä«Å×ÅÍÀÇ ½ÃÀå ÀáÀç·ÂÀ» È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ´õ ³ªÀº ¹è¾× È¿À²À» Á¦°øÇÏ´Â ¹Ì¼¼ Á÷°æÄ«Å×ÅÍ, Ç×±Õ ÄÚÆÃ, µðÁöÅÐ ¹è¾× ½Ã½ºÅÛ°úÀÇ ÅëÇÕ µî Ä«Å×ÅÍ ¼³°èÀÇ ¹ßÀüÀº ¾ÈÀü¼º°ú ÀÓ»ó °á°ú¸¦ °³¼±ÇÏ¿© Ä«Å×ÅÍ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Á¦Á¶¾÷üµéÀº ¼±Áø±¹°ú ½ÅÈï±¹ ½ÃÀåÀ» ¸ðµÎ °Ü³ÉÇØ È丷 Ä«Å×ÅÍ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ´Â µ¥ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó ¼ö¿ä Áõ°¡, ±â¼ú Çõ½Å, ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ È¯ÀÚ ¼±È£µµ, ¾Ï ¹× ¿ÏÈ­ Ä¡·á¿¡¼­ Èä°­ ¹è¾× Ä«Å×ÅÍÀÇ »ç¿ë È®´ë µî ¿©·¯ ¿äÀÎÀ» Á¾ÇÕÇϸé Èä°­ ¹è¾× Ä«Å×ÅÍ´Â Àüü Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ ¼ºÀå¿¡ Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Ãß¼¼¸¦ °¨¾ÈÇÒ ¶§, Èä°­ ¹è¾× Ä«Å×ÅÍ Ä«Å×°í¸®´Â 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ¼ºÀåÀ» âÃâÇÏ¿© Àüü Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì°¡ Àüü Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù:

ºÏ¹Ì´Â 2024³â Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áö¿ªÀû ¿ìÀ§´Â Àα¸ µ¿Çâ, ÀÓ»óÀû ¿ä±¸, ±â¼ú ¹ßÀüÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ½ÃÀå ¼ö¿ä¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀº ¾Ï ȯÀÚÀÇ Áõ°¡, ƯÈ÷ Èä¼ö Àú·ù ȯÀÚ´Â ÀϹÝÀûÀ¸·Î Èä°­ ¹è¾× Ä«Å×ÅÍ·Î °ü¸®ÇÏ´Â °ÍÀÌ ÀϹÝÀûÀÔ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ½ÃÀå ÁøÀÔÀÚÀÇ Á¸Àç¿Í È®¸³µÈ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇØ ºÏ¹Ì´Â 2025³âºÎÅÍ 2032³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È Èä°­ ¹è¾× Ä«Å×ÅÍÀÇ ÁÖ¿ä ½ÃÀåÀ¸·Î¼­ÀÇ ÁöÀ§¸¦ ´õ¿í °ø°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, GLOBOCAN(2024³â)¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â ±â°üÁö, ±â°üÁö, Æó¾ÏÀÌ 22¸¸ 6,033°ÇÀÌ º¸°íµÇ¾î ÀÌ Áö¿ª ¾Ï ¹ß»ýÀÇ 87.9%¸¦ Â÷ÁöÇÕ´Ï´Ù. ¸¶Âù°¡Áö·Î ij³ª´Ù´Â 2022³â¿¡ 3¸¸ 1,157°ÇÀ» ±â·ÏÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¾ÏÀº Á¾Á¾ ¾Ç¼º Èä¼ö¿Í °°Àº ÇÕº´ÁõÀ» À¯¹ßÇϸç, È¿°úÀûÀΠü¾× °ü¸®¸¦ À§ÇØ Èä°­ ¹è¾× Ä«Å×Å͸¦ Æ÷ÇÔÇÑ ÈäºÎ ÁßÀ縦 ÇÊ¿ä·Î ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀÇ À¯º´·üÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ½Å·ÚÇÒ ¼ö ÀÖ°í È¿À²ÀûÀÎ ¹è¾× ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¹Ì±¹ ³» ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ³ëÀεéÀº Á¾¾ç Áúȯ°ú ¸¸¼º ½ÉÆó Áúȯ¿¡ °É¸®±â ½¬¿ì¸ç, Èä°­ ¹è¾× ½Ã½ºÅÛÀ» Æ÷ÇÔÇÑ ÈäºÎ ÁßÀç°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. Æó¿Í ½ÉÀå ÁÖº¯ÀÇ Ã¼¾× Àú·ù¸¦ °ü¸®Çϱâ À§ÇÑ Á¶±â Áø´Ü ¹× Àû½Ã °³ÀÔÀÇ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ½Ã¼³ Àü¹Ý¿¡ °ÉÃÄ Èä°­ ¹è¾× Ä«Å×ÅÍÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

½ÉÇ÷°üÁúȯ ¶ÇÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC, 2024³â)¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â 20¼¼ ÀÌ»ó ¼ºÀÎ 20¸í Áß 1¸íÀÌ °ü»óµ¿¸Æ¼º ½ÉÀåÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, ¿¬°£ ¾à 80¸¸ 5,000¸íÀÌ ½ÉÀ帶ºñ¸¦ °æÇèÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ °æ¿ì ´ëºÎºÐ ¼ö¼ú ÈÄ ¹è¾× ¹× ½É³¶¾× Àú·ù °ü¸®°¡ ÇÊ¿äÇϸç, ÇÕº´Áõ ¿¹¹æ ¹× ȸº¹À» Áö¿øÇϱâ À§ÇØ Èä°­ ¹è¾× Ä«Å×ÅͰ¡ ÀÏ»óÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ÁöÁöÀûÀÎ ÀÇ·á ÀÎÇÁ¶ó, °­·ÂÇÑ »óȯ Á¤Ã¥, BD, Cook, Teleflex Incorporated¿Í °°Àº ÁÖ¿ä ½ÃÀå ÁøÀÔÀÚÀÇ Á¸Àç´Â ÇâÈÄ ¸î ³â µ¿¾È ÀÌ Áö¿ªÀ» ¼¼°è Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ Áö¹èÀûÀÎ ±â¿©ÀÚ·Î ÀÚ¸®¸Å±èÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Õ¼­ ¾ð±ÞÇÑ ¿äÀÎÀ» Á¾ÇÕÇϸé 2025³âºÎÅÍ 2032³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀº Ȱ¼ºÈ­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µé

Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ½ÃÀå Âü¿©Àڷδ BD, Teleflex Incorporated, Cook, ICU Medical, Redax S.p.A., Cardinal Health, Mediplus Ltd., Medela AG, Rocket Medical plc., Utah Medical Products, Inc., ANGIPLAST PRIVATE LIMITED, Vygon, Getinge AB, Poly Medicure Ltd., Sterimed Group µîÀÌ ÀÖ½À´Ï´Ù.

Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ ÃÖ±Ù °³¹ß Ȱµ¿:

  • 2021³â 6¿ù, ÀÇ·á ±â¼ú ºÐ¾ßÀÇ ¼¼°è ¸®´õÀÎ BD´Â PeritX(TM) º¹¸· Ä«Å×ÅÍ ½Ã½ºÅÛ¿¡ ´ëÇØ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ 510(k) Çã°¡¸¦ ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ º¹¸· Ä«Å×ÅÍ ½Ã½ºÅÛÀº º¹°­ ³» ü¾× Àú·ù¸¦ Ư¡À¸·Î ÇÏ´Â Áõ»ó¼º ¹× Àç¹ß¼º ºñ¾Ç¼º º¹¼öÀÇ ¹è¾×¿¡ »ç¿ëµË´Ï´Ù.

Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå Á¶»ç º¸°í¼­ÀÇ ÁÖ¿ä ³»¿ë

  • Èä°­ ¹è¾× Ä«Å×ÅÍÀÇ ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®(2024³â) ¹× 8³â(2025-2032³â) ½ÃÀå Àü¸Á
  • ÃÖ±Ù 3³â°£ ÁÖ¿ä Á¦Ç°/±â¼ú °³¹ß, ÇÕº´, Àμö, Á¦ÈÞ, ÇÕÀÛÅõÀÚ
  • Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷µé
  • Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå¿¡¼­ °æÀï»çµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ ±âȸµé
  • 2024³â¿¡ °¡Àå ³ôÀº ºñÁßÀ» Â÷ÁöÇÒ ºÎ¹®Àº ¹«¾ùÀ̸ç, 2032³â ÀÌµé ºÎ¹®ÀÇ ½ÇÀûÀº ¾î¶»°Ô µÉ±î?
  • ÇöÀç Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå ½Ã³ª¸®¿À¿¡¼­ »óÀ§±ÇÀ» Â÷ÁöÇϰí ÀÖ´Â Áö¿ª ¹× ±¹°¡µé
  • ÇâÈÄ ±â¾÷ÀÌ Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ ¼ºÀå ±âȸ¿¡ ÁýÁßÇØ¾ß ÇÒ Áö¿ª ¹× ±¹°¡

ÀÌ Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå Á¶»ç º¸°í¼­ÀÇ ÇýÅÃÀ» ´©¸± ¼ö ÀÖ´Â ´ë»óÀº ´ÙÀ½°ú °°½À´Ï´Ù.

  • Èä°­ ¹è¾× Ä«Å×ÅÍ Á¦Ç° Á¦°ø¾÷ü
  • ¿¬±¸±â°ü ¹× ÄÁ¼³ÆÃ ȸ»ç
  • Èä°­ ¹è¾× Ä«Å×ÅÍ °ü·Ã ´Üü, Çùȸ, Æ÷·³, ±âŸ
  • °ü°ø¼­, ±â¾÷
  • ½ºÅ¸Æ®¾÷, º¥Ã³ ijÇÇÅÐ, ºñ»óÀå±â¾÷
  • Èä°­ ¹è¾×¿ë Ä«Å×Å͸¦ Ãë±ÞÇÏ´Â À¯Åë¾÷ü ¹× ¹«¿ª¾÷ü
  • Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå ¹× Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ Ãֽбâ¼ú °³¹ß¿¡ ´ëÇØ ÀÚ¼¼È÷ ¾Ë°í ½Í¾îÇÏ´Â ´Ù¾çÇÑ ÃÖÁ¾»ç¿ëÀÚ

Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå °ü·Ã ÀÚÁÖ ¹¯´Â Áú¹®µé

1. Èä°­ ¹è¾× Ä«Å×ÅͶõ ¹«¾ùÀΰ¡?

  • Èä°­ ¹è¾× Ä«Å×ÅÍ´Â Èä°­ Ä«Å×ÅÍ ¶Ç´Â È丷 Ä«Å×ÅͶó°íµµ Çϸç, Æó¿Í ½ÉÀå ÁÖº¯¿¡¼­ °ø±â, ü¾×, Ç÷¾×, °í¸§ µîÀ» Á¦°ÅÇϱâ À§ÇØ È丷°­°ú Á¾°Ýµ¿¿¡ »ðÀԵǴ À¯¿¬ÇÑ Æ©ºêÀÔ´Ï´Ù. ±âÈä, Ç÷Èä, Èä¼ö Àú·ù, ÈäºÎ ¹× ½ÉÀå ¼ö¼ú ÈÄ ¼ö¼ú ÈÄ ¹è¾× µîÀÇ Ä¡·á¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Ä«Å×Åʹ ȣÈíÀ» Á¤»óÀ¸·Î µÇµ¹¸®°í, ÆóÇãÅ»À» ¿¹¹æÇϰí, °¨¿° ¹× ±âŸ ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Ä«Å×ÅÍ´Â ÀÀ±Þ, ¼ö¼ú ¹× ÁßȯÀÚ Ä¡·á ÇöÀå¿¡¼­ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù.

2. Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå

  • Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀº 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È 4.78%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

3. Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ ÃËÁø¿äÀÎ

  • Èä°­ ¹è¾× Ä«Å×ÅÍ¿¡ ´ëÇÑ ¼ö¿ä´Â ¾Ï, ½ÉÇ÷°üÁúȯ, ¾Ç¼º Èä¼ö, ±âÈä, Ç÷Èä, ½É³¶¾× Àú·ù¿Í °°Àº ¸¸¼ºÁúȯÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡¿Í °°ÀÌ Èä°­ ¹è¾× ÁßÀ縦 ÀÚÁÖ ÇÊ¿ä·Î ÇÏ´Â ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Ä«Å×ÅÍ ±â¼úÀÇ ¹ßÀü, ÀÇ·á ¼­ºñ½º Á¢±Ù¼º Çâ»ó, ÁÖ¿ä ½ÃÀå ÁøÀÔÀÚµéÀÇ Áö¼ÓÀûÀÎ Á¦Ç° Çõ½Å°ú ÇÔ²² ÀÌ·¯ÇÑ Áúº´À¸·Î ÀÎÇÑ ºÎ´ã Áõ°¡´Â ½ÃÀå È®´ë¸¦ ÃËÁøÇϴ ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇյǾî 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È Èä°­ ¹è¾× Ä«Å×ÅÍ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Çö´ë ÀÇÇп¡¼­ Èä°­ ¹è¾× Ä«Å×ÅÍÀÇ Áß¿äÇÑ ¿ªÇÒÀÌ °­È­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

4. Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù.

  • Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ½ÃÀå Âü¿©Àڷδ BD, Teleflex Incorporated, Cook, ICU Medical, Redax S.p.A., Cardinal Health, Mediplus Ltd., Medela AG, Rocket Medical plc., Utah Medical Products, Inc., ANGIPLAST PRIVATE LIMITED, Vygon, Getinge AB, Poly Medicure Ltd., Sterimed Group µîÀÌ ÀÖ½À´Ï´Ù.

5. Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå¿¡¼­ °¡Àå ³ôÀº Á¡À¯À²À» °¡Áø Áö¿ª

  • 2024³â Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå¿¡¼­ ºÏ¹Ì´Â ¸î °¡Áö ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÎÇØ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Áö¿ªÀû ¿ìÀ§´Â Àα¸ µ¿Çâ, ÀÓ»óÀû ¿ä±¸, ±â¼ú ¹ßÀüÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ½ÃÀå ¼ö¿ä Áõ°¡¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀº ¾Ï ȯÀÚÀÇ Áõ°¡, ƯÈ÷ Èä¼ö Àú·ù·Î ÀÎÇØ Èä°­ ¹è¾× Ä«Å×ÅÍ·Î °ü¸®µÇ´Â ȯÀÚµéÀÇ Áõ°¡ÀÔ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ½ÃÀå ÁøÀÔÀÚÀÇ Á¸Àç¿Í È®¸³µÈ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇØ ºÏ¹Ì´Â 2025³âºÎÅÍ 2032³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È Èä°­ ¹è¾× Ä«Å×ÅÍÀÇ ÁÖ¿ä ½ÃÀåÀ¸·Î¼­ÀÇ ÁöÀ§¸¦ ´õ¿í °ø°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå º¸°í¼­ ¼Ò°³

Á¦2Àå Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå ÁÖ¿ä ¿ä¾à

Á¦3Àå °æÀï ±¸µµ

Á¦4Àå ±ÔÁ¦ ºÐ¼®

  • ¹Ì±¹
  • À¯·´
  • ÀϺ»
  • Áß±¹

Á¦5Àå Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀåÀÇ ÁÖ¿ä ¿äÀÎ ºÐ¼®

  • Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼ºÁúȯ Áõ°¡
    • ÃÖ¼Òħ½À, µðÁöÅÐ, ¿µ»ó À¯µµ ¼ö¼ú ä¿ë Áõ°¡
  • Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
    • Èä°­ ¹è¾× Ä«Å×ÅÍÀÇ º¹À⼺°ú ÇѰè
    • ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç
  • Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå ±âȸ
    • ºñƲ¸² ¹æÁö ¹× Ç×±Õ ÄÚÆÃÀÌ Àû¿ëµÈ ¼Ò±¸°æ ¹× »ýü ÀûÇÕ¼º Ä«Å×ÅÍ¿Í °°Àº Ä«Å×ÅÍ ¼³°èÀÇ Çõ½Å

Á¦6Àå Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå : Porter's Five Forces ºÐ¼®

Á¦7Àå Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå Æò°¡

  • Á¦Ç° À¯Çüº°
    • ÈäºÎ Ä«Å×ÅÍ
    • È丷 ¹è¾× Ä«Å×ÅÍ
    • Åõ°üħ Ä«Å×ÅÍ
    • ±âŸ
  • ¼ÒÀ纰
    • ½Ç¸®ÄÜ
    • PVC(Æú¸®¿°È­ºñ´Ò)
  • ¿ëµµº°
    • ½ÉÀåÈäºÎ¿Ü°ú
    • Èä¼ö
    • ¿Ü»ó ¼ö¼ú
    • ±âÈä
  • ÃÖÁ¾»ç¿ëÀÚº°
    • º´¿ø
    • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • Áö¿ªº°
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ±âŸ Áö¿ª

Á¦8Àå Èä°­ ¹è¾× Ä«Å×ÅÍ ½ÃÀå ±â¾÷°ú Á¦Ç° ÇÁ·ÎÆÄÀÏ

  • BD
  • Teleflex Incorporated
  • Cook
  • ICU Medical
  • Redax S.p.A.
  • Cardinal Health
  • Mediplus Ltd.
  • Medela AG
  • Rocket Medical plc.
  • Utah Medical Products, Inc.
  • ANGIPLAST PRIVATE LIMITED
  • Vygon
  • Getinge AB
  • Poly Medicure Ltd.
  • Sterimed Group

Á¦9Àå KOLÀÇ °ßÇØ

Á¦10Àå ÇÁ·ÎÁ§Æ® Á¢±Ù¹ý

Á¦11Àå DelveInsight ¼Ò°³

Á¦12Àå ¸éÃ¥»çÇ×°ú ¹®ÀÇ

ksm 25.07.30

Chest Drainage Catheters Market by Product Type (Thoracic Catheters, Pleural Drainage Catheters, Trocar Catheters, and Others), Material (Silicone, PVC (Polyvinyl Chloride), and Others), Application (Cardiothoracic Surgery, Pleural Effusion, Trauma Surgery, Pneumothorax, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising instances of chronic disorders and increased adoption of minimally invasive, digital, and image-guided procedures across the world.

The chest drainage catheters market is estimated to grow at a CAGR of 4.78% during the forecast period from 2025 to 2032. The demand for chest drainage catheters is being driven by several critical factors, including the rising global prevalence of chronic conditions such as cancer, cardiovascular diseases, malignant pleural effusions, pneumothorax, hemothorax, and pericardial effusions, all of which frequently require thoracic drainage interventions. The growing burden of these conditions, along with advancements in catheter technology, increased healthcare access, and continued product innovation by key market players, is creating a supportive environment for market expansion. Collectively, these factors are propelling demand and reinforcing the critical role of chest drainage catheters in modern clinical care during the forecast period from 2025 to 2032.

Chest Drainage Catheters Market Dynamics:

According to data from the International Agency for Research on Cancer (2024), in the year 2022, there were 24,80,675 reported cases of Trachea, bronchus, and lung cancer. Out of which Asia accounted for 63.1% of all the cases.

These types of cancers, particularly lung are often associated with recurrent pleural effusions, a condition managed using tunneled or non-tunneled chest drainage catheters for palliative and therapeutic care. The growing cancer burden, especially in advanced-stage disease, is directly increasing the demand for such catheter systems across hospitals, oncology centers, and home care settings.

In addition to oncology, the prevalence of cardiovascular diseases is also a significant driver. According to the British Heart Foundation (2024), approximately 620 million people globally were living with heart and circulatory diseases, and 1 in 13 individuals worldwide was affected by such conditions. Cardiovascular events, such as heart attacks and cardiac surgeries, frequently result in pericardial effusions or postoperative fluid accumulation, necessitating the use of closed-system chest drainage catheters to prevent cardiac tamponade and promote recovery.

Furthermore, the increased adoption of minimally invasive, digital, and image-guided procedures is significantly boosting the chest drainage catheter market by enhancing procedural precision, patient safety, and recovery outcomes. Minimally invasive techniques reduce trauma, lower the risk of infection, and shorten hospital stays, making them highly preferred by both clinicians and patients. Image-guided catheter placements especially those using ultrasound or fluoroscopy enable accurate positioning, minimizing complications such as tissue damage or malposition. Digital innovations, such as smart catheters equipped with flow sensors and pressure monitors, are enabling real-time drainage monitoring, early detection of complications, and better postoperative management. These advancements not only improve clinical efficiency and patient outcomes but also align with global healthcare trends favoring outpatient care and cost-effective solutions.

Therefore, the increasing global burden of cancer and heart disease is driving the need for safe, effective, and minimally invasive thoracic drainage solutions, which in turn is expected to significantly boost the growth of the chest drainage catheters market during the forecast period from 2025 to 2032.

However, the complexity and limitations associated with chest drainage catheters, and stringent regulatory requirements, among others are some of the key constraints that may limit the growth of the chest drainage catheters market.

Chest Drainage Catheters Market Segment Analysis:

Product Type (Thoracic Catheters, Pleural Drainage Catheters, Trocar Catheters, and Others), Material (Silicone, PVC (Polyvinyl Chloride), and Others), Application (Cardiothoracic Surgery, Pleural Effusion, Trauma Surgery, Pneumothorax, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the chest drainage catheters market, the pleural drainage catheters category is estimated to account for the largest market share in 2024. Pleural drainage catheters are significantly boosting the overall chest drainage catheter market due to their growing use in the management of pleural effusions, pneumothorax, hemothorax, and other thoracic conditions requiring fluid or air evacuation from the pleural cavity. With the rising incidence of pleural diseases often linked to lung cancer, congestive heart failure, infections, and trauma the demand for pleural drainage solutions has increased steadily across both acute care and long-term care settings.

These catheters, especially tunneled indwelling pleural catheters (TIPCs) such as the PleurX(TM) system, have become the preferred solution for managing recurrent or chronic pleural fluid accumulation, offering a less invasive, outpatient-based alternative to repeated thoracentesis or hospital-based procedures. These catheters, offer a less invasive and more patient-friendly alternative to repeated thoracentesis and hospital-based procedures, enabling outpatient and even home-based care. This shift toward minimally invasive and ambulatory care practices aligns with broader healthcare trends, including cost containment, reduced hospital stays, and improved patient comfort, which in turn expands the market potential for pleural drainage catheters.

Furthermore, ongoing advancements in catheter design such as smaller diameter catheters with better drainage efficiency, anti-microbial coatings, and integration with digital drainage systems are enhancing safety and clinical outcomes, further encouraging adoption. As a result, manufacturers are investing in expanding their pleural catheter product portfolios, targeting both developed and emerging markets. Collectively, the rising clinical demand, technological innovation, patient preference for less invasive care, and the expanding use of pleural drainage catheters in cancer and palliative care are making them a critical driver of growth in the overall chest drainage catheter market.

Given these trends, the pleural drainage catheters category is expected to generate substantial growth and significantly contribute to the overall expansion of the chest drainage catheters market throughout the forecast period of 2025 to 2032.

North America is expected to dominate the overall chest drainage catheters market:

North America is projected to hold the largest share of the chest drainage catheters market in 2024, driven by several key factors. This regional dominance is largely driven by a combination of demographic trends, clinical needs, and technological advancements that collectively contribute to strong market demand. A key growth factor is the increasing number of cancer patients, particularly those suffering from malignant pleural effusions, a condition commonly managed with chest drainage catheters. Additionally, the presence of key market players and a well-established healthcare infrastructure further solidify North America's position as the leading market for chest drainage catheters throughout the forecast period from 2025 to 2032.

For instance, according to GLOBOCAN (2024), the United States reported 226,033 cases of trachea, bronchus, and lung cancers, accounting for 87.9% of such cases in the region. Similarly, Canada recorded 31,157 cases in 2022. These cancers frequently lead to complications such as malignant pleural effusions, which require thoracic interventions involving chest drainage catheters for effective fluid management. As the prevalence of these conditions continues to rise, so does the need for reliable and efficient drainage systems, thereby propelling market growth.

Furthermore, the growing geriatric population in the U.S. is significantly contributing to market expansion. Older adults are more prone to developing both oncological conditions and chronic cardiopulmonary diseases, which often require thoracic interventions involving chest drainage systems. The increasing need for early diagnosis and timely intervention in managing fluid accumulation around the lungs and heart is propelling the adoption of chest drainage catheters across healthcare facilities.

Cardiovascular diseases are another key factor fueling demand. According to the Centers for Disease Control and Prevention (CDC, 2024), 1 in 20 adults aged 20 and older suffers from coronary heart disease in the U.S., and approximately 805,000 people experience heart attacks annually.

Many of these cases require post-surgical drainage or management of pericardial effusions, where chest drainage catheters are routinely employed to prevent complications and support recovery.

In addition, the supportive healthcare infrastructure, strong reimbursement policies, and the presence of key market players such as BD, Cook, and Teleflex Incorporated also position the region as a dominant contributor to the global chest drainage catheters market in the upcoming years.

Collectively, the aforementioned factors are expected to boost the market for chest drainage catheters in North America during the forecast period from 2025 to 2032.

Chest Drainage Catheters Market Key Players:

Some of the key market players operating in the chest drainage catheters market include BD, Teleflex Incorporated, Cook, ICU Medical, Redax S.p.A., Cardinal Health, Mediplus Ltd., Medela AG, Rocket Medical plc., Utah Medical Products, Inc., ANGIPLAST PRIVATE LIMITED, Vygon, Getinge AB, Poly Medicure Ltd., Sterimed Group, and others.

Recent Developmental Activities in the Chest Drainage Catheters Market:

  • In June 2021, BD, a global leader in medical technology, announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PeritX(TM) Peritoneal Catheter System. The device is intended for the drainage of symptomatic, recurrent non-malignant ascites, a debilitating condition characterized by the accumulation of fluid in the abdominal cavity.

Key takeaways from the chest drainage catheters market report study

  • Market size analysis for current chest drainage catheters market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the chest drainage catheters market.
  • Various opportunities available for the other competitors in the chest drainage catheters market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current chest drainage catheters market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for chest drainage catheter market growth in the coming future?

Target audience who can benefit from this chest drainage catheters market report study

  • Chest drainage catheter product providers
  • Research organizations and consulting companies
  • Chest drainage catheters-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in chest drainage catheters
  • Various end-users who want to know more about the chest drainage catheters market and the latest technological developments in the chest drainage catheters market.

Frequently Asked Questions for the Chest Drainage Catheters Market:

1. What are chest drainage catheters?

  • Chest drainage catheters, also known as thoracic or pleural catheters, are flexible tubes inserted into the pleural space or mediastinum to remove air, fluid, blood, or pus from around the lungs or heart. They are essential in treating conditions such as pneumothorax, hemothorax, pleural effusion, and postoperative drainage following thoracic or cardiac surgery. These catheters help restore normal breathing mechanics, prevent lung collapse, and reduce the risk of infection or other complications. They are commonly used in emergency, surgical, and critical care settings.

2. What is the market for chest drainage catheters?

  • The chest drainage catheters market is estimated to grow at a CAGR of 4.78% during the forecast period from 2025 to 2032.

3. What are the drivers for the chest drainage catheters market?

  • The demand for chest drainage catheters is being driven by several critical factors, including the rising global prevalence of chronic conditions such as cancer, cardiovascular diseases, malignant pleural effusions, pneumothorax, hemothorax, and pericardial effusions, all of which frequently require thoracic drainage interventions. The growing burden of these conditions, along with advancements in catheter technology, increased healthcare access, and continued product innovation by key market players, is creating a supportive environment for market expansion. Collectively, these factors are propelling demand and reinforcing the critical role of chest drainage catheters in modern clinical care during the forecast period from 2025 to 2032

4. Who are the key players operating in the chest drainage catheters market?

  • Some of the key market players operating in the chest drainage catheters market include BD, Teleflex Incorporated, Cook, ICU Medical, Redax S.p.A., Cardinal Health, Mediplus Ltd., Medela AG, Rocket Medical plc., Utah Medical Products, Inc., ANGIPLAST PRIVATE LIMITED, Vygon, Getinge AB, Poly Medicure Ltd., Sterimed Group, and others.

5. Which region has the highest share in the chest drainage catheters market?

  • North America is projected to hold the largest share of the chest drainage catheters market in 2024, driven by several key factors. This regional dominance is largely driven by a combination of demographic trends, clinical needs, and technological advancements that collectively contribute to strong market demand. A key growth factor is the increasing number of cancer patients, particularly those suffering from malignant pleural effusions, a condition commonly managed with chest drainage catheters. Additionally, the presence of key market players and a well-established healthcare infrastructure further solidify North America's position as the leading market for chest drainage catheters throughout the forecast period from 2025 to 2032.

Table of Contents

1. Chest Drainage Catheters Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Chest Drainage Catheters Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Chest Drainage Catheters Market Key Factors Analysis

  • 5.1. Chest Drainage Catheters Market Drivers
    • 5.1.1. Rising instances of chronic disorders
    • 5.1.2. Increased adoption of minimally invasive, digital, and image-guided procedure
  • 5.2. Chest Drainage Catheters Market Restraints and Challenges
    • 5.2.1. Complexity and limitations associated with chest drainage catheters
    • 5.2.2. Stringent regulatory requirement
  • 5.3. Chest Drainage Catheters Market Opportunity
    • 5.3.1. Innovation in catheter design such as smaller-bore and biocompatible catheters with anti-kinking and anti-microbial coatings

6. Chest Drainage Catheters Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Chest Drainage Catheters Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Thoracic Catheters
    • 7.1.2. Pleural Drainage Catheters
    • 7.1.3. Trocar Catheters
    • 7.1.4. Others
  • 7.2. By Material
    • 7.2.1. Silicone
    • 7.2.2. PVC (Polyvinyl Chloride)
    • 7.2.3. Others
  • 7.3. By Application
    • 7.3.1. Cardiothoracic Surgery
    • 7.3.2. Pleural Effusion
    • 7.3.3. Trauma Surgery
    • 7.3.4. Pneumothorax
    • 7.3.5. Others
  • 7.4. By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Ambulatory Surgical Centers
    • 7.4.3. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.1.2. Canada Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.1.3. Mexico Chest Drainage Catheters Market Size in USD million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.2.2. Germany Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.2.3. United Kingdom Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.2.4. Italy Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.2.5. Spain Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.2.6. Rest of Europe Chest Drainage Catheters Market Size in USD million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.3.2. Japan Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.3.3. India Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.3.4. Australia Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.3.5. South Korea Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific Chest Drainage Catheters Market Size in USD million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.4.2. Africa Chest Drainage Catheters Market Size in USD million (2022-2032)
      • 7.5.4.3. South America Chest Drainage Catheters Market Size In USD Million (2022-2032)

8. Chest Drainage Catheters Market Company and Product Profiles

  • 8.1. BD
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Teleflex Incorporated
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Cook
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. ICU Medical
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Redax S.p.A.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Cardinal Health
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Mediplus Ltd.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Medela AG
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Rocket Medical plc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Utah Medical Products, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. ANGIPLAST PRIVATE LIMITED
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Vygon
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Getinge AB
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Poly Medicure Ltd.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Sterimed Group
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦